Article Text

PDF
FRI0147 IgG4 antibody response upon long term treatment with adalimumab
  1. P. van Schouwenburg1,
  2. C. Krieckaert2,
  3. M. Nurmohamed2,
  4. T. Rispens1,
  5. L. Aarden1,
  6. D. Wouters1,
  7. G. Wolbink1,2
  1. 1Immunopathology, Sanquin Research
  2. 2Jan van Breemen Institure | Reade, Amsterdam, Netherlands

Abstract

Background A substantial part of the rheumatoid arthritis (RA) patients is chronically treated with adalimumab. Some of these patients produce antibodies against adalimumab, which correlate with lower serum drug levels and reduced clinical response. Long term exposure to antigens may result in antigen specific IgG4 production as demonstrated in previous studies on prolonged exposure to antigens such as bee venom, factor VIII and IFN-β.

Objectives Here we investigate whether long term treatment of RA patients with the therapeutic monoclonal antibody adalimumab leads to the production of specific IgG4 antibodies.

Methods We developed radio immunoassays to detect total IgG or IgG4 against adalimumab and applied these in a cohort of 272 RA patients during three years of adalimumab treatment.

Results Of the 272 patients 32% developed antibodies against adalimumab. We observed that a fast majority of the patients also produce IgG4 antibodies against adalimumab (29%). The proportion IgG4 of total IgG against adalimumab varies widely between patients (median; 25-75 percentile 38; 21-67%). In some patients the antibody response even seems to be dominated by IgG4.

Conclusions The role of IgG4 in the immune response against adalimumab is variable in adalimumab treated RA patients. Although IgG4 is often considered to be harmless, because of its lack of effector function, these patients show low adalimumab levels and reduced clinical response.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.